STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
批准号:
10229423
负责人:
Jinming Gao
金额:
$53.55万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-30 至 2022-08-31
关键词:
AnimalsAntigensCancer CenterCell physiologyClinicalClinical DataCombined Modality TherapyCytotoxic T-LymphocytesDendritic CellsDoseGoalsGuidelinesHistologyHuman PapillomavirusImmuneImmune checkpoint inhibitorImmune systemImmunocompetentIndividualInterferon ActivationInterferon Type ILarge Intestine CarcinomaLifeMC38Malignant NeoplasmsModelingMusMutateNanotechnologyNatureOrganPathway interactionsPatientsPeptidesPharmacology StudyPhasePolymersProductionProteinsProtocols documentationResearch PersonnelSafetyT cell responseT cell therapyT-LymphocyteTestingTherapeuticTissuesToxic effectTumor AntigensTumor ImmunityVaccine AdjuvantVaccinesanti-CTLA4anti-PD-1armcancer carecancer immunotherapycancer therapycheckpoint inhibitioncheckpoint therapychemotherapyclinical translationcytokineimmunogenicimmunotoxicityinhibitor/antagonistipilimumablymph nodesmelanomamembernanoparticlenanovaccineneoantigensneoplasm immunotherapynovelpembrolizumabpre-clinicalpreclinical evaluationprogramsrefractory cancerresponsespatiotemporalsuccesssynergismsystemic toxicitytumortumor microenvironment
中文摘要
摘要
癌症免疫治疗正在成为通过靶向治疗癌症的新范式
而不是肿瘤。几种检查点抑制剂的临床批准(例如,
Ipilimumab,Pembrolizumab)在一小部分黑色素瘤患者中显示出持久的反应
而不是传统的化疗。尽管取得了这些成功,但许多癌症的免疫原性很差
并且不能产生足够的细胞毒性T淋巴细胞(CTL),
从免疫检查点疗法中获益。本申请的长期目标是建立
STING激活聚合物纳米疫苗用于黑色素瘤的细胞毒性T细胞治疗。我们将利用
发现了一种超pH敏感聚合物(PC 7A),
树突状细胞中肿瘤抗原(Ag)的胞质递送的协调和对肿瘤细胞的先天刺激
肿瘤特异性CTL的稳健产生。Ag-PC 7A NP的简单物理混合物产生了
稳健的Th 1和CTL(>80%)应答而不需要先天刺激物(即,CpG,Poly(I:C))。使用
的肿瘤相关抗原(TAA)已显示出显着增加的抗肿瘤疗效,
小鼠中的B16 F10黑素瘤模型。我们将测试中心假设,即PC 7A纳米颗粒疫苗
将与检查点抑制协同作用,以允许黑色素瘤的安全和有效的T细胞疗法。
具体目标有三:(1)将纳米疫苗平台扩展到多种黑色素瘤肽
(2)评价聚合物纳米疫苗在健康、免疫活性
(3)评价聚合物纳米疫苗的抗肿瘤功效及其与药物的协同作用。
检查点抑制上述目标的实现将为临床提供关键数据
用于黑色素瘤治疗的纳米疫苗的翻译。我们还将与其他
nanoalliance成员测试PC 7A NP在其他癌症适应症中的作用。
英文摘要
Abstract
Cancer immunotherapy is emerging as a new paradigm for the treatment of cancer by targeting
the body's immune system instead of tumor. Clinical approvals of several check point inhibitors (e.g.,
Ipilimumab, Pembrolizumab) have shown durable response in a small subset of melanoma patients
over conventional chemotherapy. Despite these successes, many cancers are poorly immunogenic
and do not generate adequate cytotoxic T lymphocytes (CTLs) and therefore these patients cannot
benefit from immune checkpoint therapies. The long-term goal of this application is to establish
STING-activating polymeric nanovaccines for cytotoxic T cell therapy of melanoma. We will capitalize
on the discovery of an ultra-pH sensitive polymer (PC7A) that allows optimal spatio-temporal
orchestration of cytosolic delivery of tumor antigen (Ag) in dendritic cells and innate stimulation for the
robust production of tumor-specific CTLs. A simple physical mixture of Ag-PC7A NP resulted in a
robust Th1 and CTL (>80%) response without the need of innate stimulants (i.e., CpG, Poly(I:C)). Use
of tumor associated antigens (TAAs) have shown significantly increased antitumor efficacy in a
B16F10 melanoma model in mice. We will test the central hypothesis that PC7A nanoparticle vaccine
will synergize with checkpoint inhibition to allow a safe and efficacious T cell therapy of melanoma.
There are three specific aims: (1) Expand the nanovaccine platform to multiple melanoma peptide
antigens; (2) Evaluate the safety of the polymeric nanovaccines in healthy, immunocompetent
animals; and (3) Evaluate the antitumor efficacy of the polymer nanovaccines and its synergy with
checkpoint inhibition. Accomplishments of the above aims will provide critical data for clinical
translation of the nanovaccines for melanoma therapy. We will also collaborate with other
nanoalliance members to test the PC7A NP in additional cancer indications.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.
肿瘤内施用 STING 激活纳米疫苗可增强 T 细胞免疫治疗
DOI:
10.1136/jitc-2021-003960
发表时间:
2022-05
期刊:
Journal for immunotherapy of cancer
影响因子:
10.9
作者:
[]
通讯作者:
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
-
批准号:9892979
-
项目类别:
-
资助金额:$37.64万
-
财政年份:2018
-
负责人:Jinming Gao
-
依托单位:
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
-
批准号:10371057
-
项目类别:
-
资助金额:$36.89万
-
财政年份:2018
-
负责人:Jinming Gao
-
依托单位:
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
-
批准号:10113555
-
项目类别:
-
资助金额:$37.64万
-
财政年份:2018
-
负责人:Jinming Gao
-
依托单位:
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
-
批准号:9982225
-
项目类别:
-
资助金额:$52.95万
-
财政年份:2017
-
负责人:Jinming Gao
-
依托单位:
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
-
批准号:9754799
-
项目类别:
-
资助金额:$51.95万
-
财政年份:2017
-
负责人:Jinming Gao
-
依托单位:
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
-
批准号:9371064
-
项目类别:
-
资助金额:$53.55万
-
财政年份:2017
-
负责人:Jinming Gao
-
依托单位:
Ultra-Responsive "ON/OFF" Fluorescent Nanoprobes for Cancer Molecular Imaging
-
批准号:8705515
-
项目类别:
-
资助金额:$35.58万
-
财政年份:2011
-
负责人:Jinming Gao
-
依托单位:
ULTRA-SENSITIVE MRI PROBES
-
批准号:8363911
-
项目类别:
-
资助金额:$1.61万
-
财政年份:2011
-
负责人:Jinming Gao
-
依托单位:
Ultra-Responsive "ON/OFF" Fluorescent Nanoprobes for Cancer Molecular Imaging
-
批准号:8193961
-
项目类别:
-
资助金额:$36.57万
-
财政年份:2011
-
负责人:Jinming Gao
-
依托单位:
Ultra-Responsive "ON/OFF" Fluorescent Nanoprobes for Cancer Molecular Imaging
-
批准号:8516037
-
项目类别:
-
资助金额:$34.59万
-
财政年份:2011
-
负责人:Jinming Gao
-
依托单位:
Ultra-Responsive "ON/OFF" Fluorescent Nanoprobes for Cancer Molecular Imaging
-
批准号:8310213
-
项目类别:
-
资助金额:$36.67万
-
财政年份:2011
-
负责人:Jinming Gao
-
依托单位:
ULTRA-SENSITIVE MRI PROBES
-
批准号:8171662
-
项目类别:
-
资助金额:$1.05万
-
财政年份:2010
-
负责人:Jinming Gao
-
依托单位:
ULTRA-SENSITIVE MRI PROBES
-
批准号:7956982
-
项目类别:
-
资助金额:$1.78万
-
财政年份:2009
-
负责人:Jinming Gao
-
依托单位:
ULTRA-SENSITIVE MRI PROBES
-
批准号:7724132
-
项目类别:
-
资助金额:$1.05万
-
财政年份:2008
-
负责人:Jinming Gao
-
依托单位:
Ultra-Sensitive MR Probes for Molecular Diagnosis of Lung Cancer
-
批准号:7653724
-
项目类别:
-
资助金额:$32.58万
-
财政年份:2008
-
负责人:Jinming Gao
-
依托单位:
Ultra-Sensitive MR Probes for Molecular Diagnosis of Lung Cancer
-
批准号:8077956
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2008
-
负责人:Jinming Gao
-
依托单位:
Ultra-Sensitive MR Probes for Molecular Diagnosis of Lung Cancer
-
批准号:7531393
-
项目类别:
-
资助金额:$32.58万
-
财政年份:2008
-
负责人:Jinming Gao
-
依托单位:
Ultra-Sensitive MR Probes for Molecular Diagnosis of Lung Cancer
-
批准号:7809639
-
项目类别:
-
资助金额:$32.58万
-
财政年份:2008
-
负责人:Jinming Gao
-
依托单位:
Micellar Nanotherapeutics for Targeted Lung Cancer Therapy
-
批准号:7414099
-
项目类别:
-
资助金额:$26.85万
-
财政年份:2007
-
负责人:Jinming Gao
-
依托单位:
Micellar Nanotherapeutics for Targeted Lung Cancer Therapy
-
批准号:7564714
-
项目类别:
-
资助金额:$26.85万
-
财政年份:2007
-
负责人:Jinming Gao
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: